摘要
主动脉瘤是一个重要的临床问题,因为它们在破裂之前基本上没有被发现。目前,对动脉瘤形成机制的了解是有限的。大量研究清楚地表明,血管平滑肌细胞在血管对血流动力学变化的发展和反应中起着重要作用,这些反应中的缺陷可能导致动脉瘤的形成。LDL受体相关蛋白1(LRP 1)是一种主要的平滑肌细胞受体,具有介导多种配体内吞,启动和调控信号通路的功能。人类和小鼠模型中的遗传学证据揭示了LRP 1在维持血管完整性方面的重要作用。了解实现这一目标的机制,涉及LRP 1调节已知的降解细胞外基质的蛋白酶水平的能力以及调节信号事件的能力,可能是一个重要的研究领域。
关键词: 脂蛋白受体,LRP 1,蛋白酶,动脉瘤,平滑肌细胞,细胞外基质。
图形摘要
Current Drug Targets
Title:Role of the LDL Receptor-Related Protein 1 in Regulating Protease Activity and Signaling Pathways in the Vasculature
Volume: 19 Issue: 11
关键词: 脂蛋白受体,LRP 1,蛋白酶,动脉瘤,平滑肌细胞,细胞外基质。
摘要: Aortic aneurysms represent a significant clinical problem as they largely go undetected until a rupture occurs. Currently, an understanding of mechanisms leading to aneurysm formation is limited. Numerous studies clearly indicate that vascular smooth muscle cells play a major role in the development and response of the vasculature to hemodynamic changes and defects in these responses can lead to aneurysm formation. The LDL receptor-related protein 1 (LRP1) is major smooth muscle cell receptor that has the capacity to mediate the endocytosis of numerous ligands and to initiate and regulate signaling pathways. Genetic evidence in humans and mouse models reveal a critical role for LRP1 in maintaining the integrity of the vasculature. Understanding the mechanisms by which this is accomplished represents an important area of research, and likely involves LRP1’s ability to regulate levels of proteases known to degrade the extracellular matrix as well as its ability to modulate signaling events.
Export Options
About this article
Cite this article as:
Role of the LDL Receptor-Related Protein 1 in Regulating Protease Activity and Signaling Pathways in the Vasculature, Current Drug Targets 2018; 19 (11) . https://dx.doi.org/10.2174/1389450119666180511162048
DOI https://dx.doi.org/10.2174/1389450119666180511162048 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Related Journals
Related Books
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Pathogenic and Therapeutic Significance of Angiotensin II Type I Receptor in Abdominal Aortic Aneurysms
Current Drug Targets A Review of Neuroprotective Agents
Current Medicinal Chemistry Management of Blood Pressure and Heart Rate in Patients with Acute Stroke
Current Pharmaceutical Design Minocycline Mediated Mitochondrial Cytoprotection: Premises for Therapy of Cerebrovascular and Neurodegenerative Diseases
Current Drug Targets Type 1 Diabetes Mellitus - Risk Factor for Cardiovascular Disease Morbidity and Mortality
Current Diabetes Reviews Patent Foramen Ovale, the Role of Antiplatelet Therapy Alone or Anticoagulant Therapy Alone Versus Device Closure for Cryptogenic Stroke: A Review of the Literature and Current Recommendations
Cardiovascular & Hematological Agents in Medicinal Chemistry Diabetic Heart and the Cardiovascular Surgeon
Cardiovascular & Hematological Disorders-Drug Targets NLRP3 Inflammasome in the Pathophysiology of Hemorrhagic Stroke: A Review
Current Neuropharmacology Association of Oxidative Stress to the Genesis of Anxiety: Implications for Possible Therapeutic Interventions
Current Neuropharmacology Mitochondrial Triglyceride Transfer Protein Inhibition: New Achievements in the Treatment of Dyslipidemias
Current Pharmaceutical Design Clinical and Forensic Signs Related to Opioids Abuse
Current Drug Abuse Reviews Indicators of Cardiovascular Risk in Metabolic Syndrome: Long Term Follow-up in Italian Patients
Current Vascular Pharmacology Adverse Bioeffects of Ultrasound Contrast Agents Used in Echocardiography: True Safety Issue or “Much Ado About Nothing”?
Current Vascular Pharmacology New therapeutic effects of cilostazol in patients with ischemic disorders
Current Vascular Pharmacology Craniofacial Anomalies: From Development to Molecular Pathogenesis
Current Molecular Medicine Role of AGEs-RAGE System in Cardiovascular Disease
Current Pharmaceutical Design Soluble Epoxide Hydrolase Inhibitors and their Potential for Treatment of Multiple Pathologic Conditions
Current Medicinal Chemistry Extracts and Flavonoids of <i>Passiflora</i> Species as Promising Anti-inflammatory and Antioxidant Substances
Current Pharmaceutical Design 30 Years Lost in Anesthesia Theory
Cardiovascular & Hematological Agents in Medicinal Chemistry Statin Treatment Non-adherence and Discontinuation: Clinical Implications and Potential Solutions
Current Pharmaceutical Design